Undisclosed IRF5 inhibitor / Totus Medicines - LARVOL DELTA

Totus Medicines…announced the presentation of new preclinical data highlighting the discovery and proof of concept of a first-in-class covalent small molecule inhibitor of Interferon Regulatory Factor 5 (IRF5) at the American Association of Immunologists (AAI) Annual Meeting (GlobeNewswire) - "Key Highlights:...(i) Covalent target engagement confirmed by mass spectrometry; (ii) Inhibition of cytokine secretion in TLR-stimulated primary human immune cells; (iii) Selective inhibition of IRF5, but not IRF3, nuclear translocation' (iv) In vivo inhibition of pro-inflammatory cytokines in R848-treated normal and humanized mouse models; (v) Improved chemical matter demonstrates enhanced potency both in vitro and in vivo, to be presented at an upcoming scientific meeting."

Preclinical • Immunology